Match!
Evangelos N. Liberopoulos
University of Ioannina
EndocrinologyStatinCholesterolDiabetes mellitusMedicine
190Publications
38H-index
4,630Citations
What is this?
Publications 189
Newest
#1Christos V. Rizos (UoI: University of Ioannina)H-Index: 13
#2Matilda Florentin (UoI: University of Ioannina)H-Index: 14
Last. Anastasia Garoufi (UoA: National and Kapodistrian University of Athens)H-Index: 10
view all 22 authors...
Familial hypercholesterolemia (FH) is characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and increased cardiovascular disease (CVD) risk. FH patients often have increased lipoprotein(a) [Lp(a)] levels, which further increase CVD risk. Novel methods for accurately calculating LDL-C have been proposed. Patients with FH were recruited by a network of Greek sites participating in the HELLAS-FH registry. LDL-C levels were calculated using the Friedewald (LDL-CF) and the Mart...
Source
1 CitationsSource
#1Stefania Makariou (UoI: University of Ioannina)H-Index: 6
#2Anna Challa (UoI: University of Ioannina)H-Index: 19
Last. Evangelos N. Liberopoulos (UoI: University of Ioannina)H-Index: 38
view all 7 authors...
Introduction Obesity is associated with cardiovascular disease (CVD) risk factors as well as decreased 25(OH) vitamin D serum levels. We aimed to study 25(OH) vitamin D levels in adolescents with obesity compared with normal weight controls in association with CVD risk factors, and the possible effect of vitamin D supplementation. Material and methods In a cross-sectional study, 69 obese and 34 normal-weight adolescents were included. In an interventional study 15 adolescents with obesity and vi...
Source
#2Evangelos C. Rizos (UoI: University of Ioannina)H-Index: 17
Last. Evangelos N. Liberopoulos (UoI: University of Ioannina)H-Index: 38
view all 4 authors...
The CANVAS program detected a 2-fold increased risk of lower limb amputation in patients treated with canagliflozin compared with those with placebo. This adverse effect was not confirmed in the CR...
2 CitationsSource
#1Fotios Barkas (UoI: University of Ioannina)H-Index: 9
#2George Liamis (UoI: University of Ioannina)H-Index: 23
Last. Evangelos N. Liberopoulos (UoI: University of Ioannina)H-Index: 38
view all 5 authors...
Source
AimsThe aim of this study was to evaluate the effect of microsomal triglyceride transfer protein inhibitor (lomitapide) in patients with homozygous familial hypercholesterolaemia.Methods and result...
2 CitationsSource
Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9i) reduce cardiovascular events ([1][1],[2][2]). 18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography/computed tomography (PET/CT) successfully evaluates arterial inflammation and improves
1 CitationsSource
#1Loukianos S. Rallidis (UoA: National and Kapodistrian University of Athens)H-Index: 31
#2Ioannis Skoumas (UoA: National and Kapodistrian University of Athens)H-Index: 14
Last. Efstathios K. Iliodromitis (UoA: National and Kapodistrian University of Athens)H-Index: 36
view all 11 authors...
Abstract Background In randomized clinical trials, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively reduce low-density lipoprotein-cholesterol (LDL-C) with a favorable tolerability and safety profile. Our purpose is to provide real-world data regarding the indications, efficacy and safety of PCSK9i. Methods The cohort comprised 141 patients who attended the lipid clinic of 3 hospitals in Greece and started using PCSK9i. Patients were requested to attend the lipid cli...
Source
#1Fotios Barkas (UoI: University of Ioannina)H-Index: 9
#2Moses Elisaf (UoI: University of Ioannina)H-Index: 63
Last. Evangelos C. Rizos (UCY: University of Cyprus)H-Index: 2
view all 6 authors...
Abstract Aim To investigate which metabolic factors increase the risk of incident diabetes (T2D) in statin-treated patients. Methods A retrospective study conducted in Greece including 1241 consecutive individuals with dyslipidemia attending a lipid clinic for ≥3 years. After defining associations with incident T2D, we assessed the risk of new-onset T2D based on the presence of impaired fasting glucose (IFG), atherogenic dyslipidemia, and overweight/obesity. Results After excluding 166 patients ...
2 CitationsSource
Introduction: Current European guidelines recommend treatment with lipid-lowering therapy (LLT) to a low-density lipoprotein cholesterol (LDL-C) target of < 70 mg/dl for patients at very high risk. LDL-C target attainment and use of LLTs in these patients in Greece is not known. Material and methods: The Dyslipidemia International Study (DYSIS) II was a multicenter observational study. The coronary heart disease (CHD) cohort was divided into two groups based on treatment status (on LLT for ≥ 3 m...
1 CitationsSource
12345678910